Modulation of Peripheral μ-Opioid Analgesia by σ1 Receptors
Authors:
- Cristina Sánchez-FernándezCSCristina Sánchez-Fernández
- Ángeles Montilla-GarcíaÁMÁngeles Montilla-García
- Rafael González-CanoRGRafael González-Cano
- Francisco Rafael NietoFNFrancisco Rafael Nieto
- Lucía RomeroLRLucía Romero
- Antonia Artacho-CordónAAAntonia Artacho-Cordón
- Rosa MontesRMRosa Montes
- Begoña Fernández-PastorBFBegoña Fernández-Pastor
- Manuel MerlosMMManuel Merlos
- José Manuel BaeyensJBJosé Manuel Baeyens
- José Manuel EntrenaJEJosé Manuel Entrena
- Enrique José CobosECEnrique José Cobos
- 1 January 2014
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 348 (1) , 32-45
Abstract
We evaluated the effects of σ1-receptor inhibition on μ-opioid–induced mechanical antinociception and constipation. σ1-Knockout mice exhibited marked mechanical antinociception in response to several μ-opioid analgesics (fentanyl, oxycodone, morphine, buprenorphine, and tramadol) at systemic (subcutaneous) doses that were inactive in wild-type mice and even unmasked the antinociceptive effects of the peripheral μ-opioid agonist loperamide. Likewise, systemic (subcutaneous) or local (intraplantar) treatment of wild-type mice with the selective σ1 antagonists BD-1063 [1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride] or S1RA [4-[2-[[5-methyl-1-(2-naphthalenyl)1H-pyrazol-3-yl]oxy]ethyl] morpholine hydrochloride] potentiated μ-opioid antinociception; these effects were fully reversed by the σ1 agonist PRE-084 [2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate) hydrochloride], showing the selectivity of the pharmacological approach. The μ-opioid antinociception potentiated by σ1 inhibition (by σ1-receptor knockout or σ1-pharmacological antagonism) was more sensitive to the peripherally restricted opioid antagonist naloxone methiodide than opioid antinociception under normal conditions, indicating a key role for peripheral opioid receptors in the enhanced antinociception. Direct interaction between the opioid drugs and σ1 receptor cannot account for our results, since the former lacked affinity for σ1 receptors (labeled with [3H](+)-pentazocine). A peripheral role for σ1 receptors was also supported by their higher density (Western blot results) in peripheral nervous tissue (dorsal root ganglia) than in several central areas involved in opioid antinociception (dorsal spinal cord, basolateral amygdala, periaqueductal gray, and rostroventral medulla). In contrast to its effects on nociception, σ1-receptor inhibition did not alter fentanyl- or loperamide-induced constipation, a peripherally mediated nonanalgesic opioid effect. Therefore, σ1-receptor inhibition may be used as a systemic or local adjuvant to enhance peripheral μ-opioid analgesia without affecting opioid-induced constipation.Keywords
This publication has 56 references indexed in Scilit:
- Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effectsEuropean Journal of Pharmacology, 2013
- Functional Selectivity at the μ-Opioid Receptor: Implications for Understanding Opioid Analgesia and TolerancePharmacological Reviews, 2011
- Molecular Mechanisms of Opioid Receptor-dependent Signaling and BehaviorAnesthesiology, 2011
- σ1 Receptor Modulation of G-Protein-Coupled Receptor Signaling: Potentiation of Opioid Transduction Independent from Receptor BindingMolecular Pharmacology, 2010
- Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptorsPsychopharmacology, 2009
- Methylnaltrexone in the treatment of opioid-induced constipationClinical and Experimental Gastroenterology, 2008
- Differences between and combinations of opioids re-visitedCurrent Opinion in Anaesthesiology, 2008
- Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)Pain Practice, 2008
- In vivo evaluation of (+)-MR200 as a new selective sigma ligand modulating MOP, DOP and KOP supraspinal analgesiaLife Sciences, 2005
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983